Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1 - Episode 9

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma

What impact have BRAF/MEK inhibitors had, since their initial approval, and how has this changed mutation testing for melanoma?


CASE: Metastatic Melanoma

Charles, a 62-year-old Caucasian landscaper, presented to his primary care physician with fatigue, dyspnea upon exertion, and a nonproductive cough that has lasted for 6 to 8 weeks. .

  • Following a medical examination, a suspicious mole was biopsied, which resulted in a diagnosis of melanoma.
  • Genetic testing revealed aBRAFV600K mutation
  • PET/CT scan shows metastases to the lung and a soft tissue nodule in the liver (1.4 cm x 1.1 cm)
  • LDH levels and liver function test results were normal
  • The patient’s ECOG performance status was 1

Treatment was initiated with the combination of BRAF and MEK inhibitors.